December 10, 2020 07:00 AM ESTUpdated October 5, 11:13 AM
People
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women blaz­ing trails in bio­phar­ma R&D — Covid-19 and be­yond

ENDPOINTS

In the sec­ond year of End­points News’ bud­ding tra­di­tion of high­light­ing women blaz­ing trails in bio­phar­ma R&D, we’ve seen a num­ber of firsts. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times